Cross-Sector entity
Of the tracked stories, 2 of 2 also mention Bundibugyo ebolavirus, the most common co-covered peer. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. ACOREP appears in 2 tracked Cross-Sector stories from July 13, 2026.
2 verified stories tracked
Last mentioned: Jul 13, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention Bundibugyo ebolavirus, the most common co-covered peer. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. ACOREP appears in 2 tracked Cross-Sector stories from July 13, 2026. The tracked stories average 3 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ACOREP. Shared-story counts are live from our verified record — not editorial picks.
Ethics Approval Received
NanoViricides announces National Ethics Committee approval for Phase II trial of NV-387 oral gummies for Ebola.
Outbreak Worsens
DRC public health institute reports 1,926 confirmed Ebola cases and 702 deaths, with spread to Haut-Uele and Tshopo provinces.
As the DRC Ebola outbreak surpasses 1,900 cases with 702 fatalities, NanoViricides’ oral NV-387 gummies gain ethics approval for a Phase II trial. The chewable format could overcome logistical hurdles in resource-limited regions, potentially reshaping epidemic management if proven effective.
NanoViricides (NYSE American: NNVC) has crossed a major regulatory hurdle with DRC ethics committee approval for its Phase II trial of NV-387 oral gummies for Ebola. The company leverages its nanoviricide platform against an underserved Bundibugyo strain, positioning itself uniquely in the infectious disease space with a potential first-in-class oral antiviral.
Source: newjerseytelegraph.com · hawaiitelegraph.com
